Lyra Therapeutics Inc (LYRA)

Finanzdaten der Lyra Therapeutics Inc-Aktie (LYRA)

Gewinn- und Verlustrechnung

Vierteljährlich

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	264.38% 0.532	0.146	0.544	0.458	0.41
Operating Expenses	44.72% 24.06	16.62	17.37	16.96	17.72
Benefits Costs and Expenses	50.28% 22.97	15.29	16.18	16.06	16.65
Costs And Expenses	50.28% 22.97	15.29	16.18	16.06	16.65
Operating Income/Loss	42.77% -23.52	-16.48	-16.83	-16.50	-17.31
Nonoperating Income/Loss	18.83% 1.086	1.338	1.192	0.897	1.072
Income/Loss From Continuing Operations Before Tax	48.21% -22.44	-15.14	-15.63	-15.61	-16.24
Income Tax Expense/Benefit	17.65% 0.014	0.017	0.016	0.012	0.014
Income/Loss From Continuing Operations After Tax	48.14% -22.45	-15.16	-15.65	-15.62	-16.25
Net Income/Loss	48.14% -22.45	-15.16	-15.65	-15.62	-16.25
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	1,537% 64.01	3.9096	56.95	43.68	36.83
Diluted Average Shares	1,537% 64.01	3.9096	56.95	43.68	36.83
Basic Earnings Per Share	59.09% -0.35	-0.22	-0.27	-0.36	-0.44
Diluted Earnings Per Share	59.09% -0.35	-0.22	-0.27	-0.36	-0.44
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-